Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based regenerative medicine development company Eqalix has received $50,000 in funding from the Nanotechnology Institute (NTI), Pennsylvania, to advance the development of alimentary protein scaffolds (APS) for wound healing and aesthetic dermatology.
Subscribe to our email newsletter
The project was also financed in part by the Commonwealth of Pennsylvania and department of community and economic development through the funding to Ben Franklin Technology Partners of Southeastern PA.
The funding forms part of Match for Sponsored Research Program (SRA), which adds to the $125,000 Sponsored Research Agreement executed between Eqalix and Temple University.
Eqalix chairman and CEO Joseph Connell said the company is excited to receive the financial support of NTI to advance the development of OmegaSkin.
"OmegaSkin has the potential to heal full thickness wounds without scarring and has the potential to change the way we treat chronic wounds, burns and accelerate the physiologic healing in aesthetic dermatology applications," Connell added.